Harmon Face Values Minoxidil label

Harmon Face Values Minoxidil

Harmon Face Values Minoxidil Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

1.1 Treatment of Gastroesophageal Reflux Disease (GERD)

Healing of Erosive Esophagitis

Esomeprazole Magnesium Delayed-Release Capsules USP are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of Esomeprazole Magnesium Delayed-Release Capsules USP may be considered.

Maintenance of Healing of Erosive Esophagitis

Esomeprazole Magnesium Delayed-Release Capsules USP are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.

Symptomatic Gastroesophageal Reflux Disease

Esomeprazole Magnesium Delayed-Release Capsules USP are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older.

1.2 Risk Reduction of NSAID-Associated Gastric Ulcer

Esomeprazole Magnesium Delayed-Release Capsules USP are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Triple Therapy (Esomeprazole Magnesium Delayed-Release Capsules USP plus amoxicillin and clarithromycin): Esomeprazole Magnesium Delayed-Release Capsules USP, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Dosage and Administration (2) and Clinical Studies (14)].

In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the prescribing information for clarithromycin].

1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

Esomeprazole Magnesium Delayed-Release Capsules USP are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

History

There is currently no drug history available for this drug.

Other Information

The active ingredient in the proton pump inhibitor Esomeprazole Magnesium Delayed-Release Capsules USP for oral administration is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole-1-yl) magnesium dihydrate. Esomeprazole is the S-isomer of omeprazole, which is a mixture of the S- and R- isomers. (Initial U.S. approval of esomeprazole magnesium: 2001.) It has a molecular weight of 749.2 as a dihydrate and 713.1 on an anhydrous basis. The structural formula is:

structural formula

(C17H18N3O3S)2 Mg • 2 H2O M.W. 749.2

The magnesium salt is an off-white to pale yellow colored crystalline powder. It contains 2 moles of water of solvation and is slightly soluble in water. The stability of esomeprazole magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions. At pH 6.8 (buffer), the half-life of the magnesium salt is about 19 hours at 25°C and about 8 hours at 37°C.

Each Esomeprazole Magnesium Delayed-Release Capsule USP contains either 20 mg or 40 mg of esomeprazole (present as 21.69 mg or 43.38 mg esomeprazole magnesium dihydrate) in the form of enteric-coated granules. In addition, each delayed-release capsule contains the following inactive ingredients: FD&C blue #1, gelatin, hypromellose, methacrylic acid copolymer dispersion, polysorbate 80, propylene glycol, shellac, sugar spheres, talc, titanium dioxide, triethyl citrate, and yellow iron oxide.

Harmon Face Values Minoxidil Manufacturers

  • Harmon Face Values Minoxidil | Teva Pharmaceuticals Usa Inc
    No Recall

    Harmon Face Values Minoxidil | Teva Pharmaceuticals Usa Inc

    Harmon Face Values Minoxidil | Teva Pharmaceuticals Usa Inc

    Esomeprazole Magnesium Delayed-Release Capsules are supplied as delayed-release capsules for oral administration. The recommended dosages are outlined in Table 1. Esomeprazole Magnesium Delayed-Release Capsules should be taken at least one hour before meals.

    The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment.

    Table 1: Recommended Dosage Schedule of Esomeprazole Magnesium Delayed-Release Capsules

    Indication

    Dose

    Frequency

    Gastroesophageal Reflux Disease (GERD)

    Healing of Erosive Esophagitis

    20 mg or 40 mg

    Once Daily for 4 to 8 weeks*

    Maintenance of Healing of Erosive Esophagitis

    20 mg

    Once Daily**

    Symptomatic Gastroesophageal

    Reflux Disease

    20 mg

    Once Daily for 4 Weeks***

    Pediatric GERD

    12 to 17 Year Olds

    Healing of Erosive Esophagitis

    20 mg or 40 mg

    Once Daily for 4 to 8 Weeks

    Symptomatic GERD

    20 mg

    Once Daily for 4 Weeks

    1 to 11 Year Olds+

    Short-term Treatment of Symptomatic GERD

    10 mg

    Once Daily for up to 8 Weeks

    Healing of Erosive Esophagitis

    weight < 20 kg

    10 mg

    Once Daily for 8 Weeks

    weight ≥ 20 kg

    10 mg or 20 mg

    Once Daily for 8 Weeks

    Risk Reduction of NSAID-Associated Gastric Ulcer

    20 mg or 40 mg

    Once Daily for up to 6 months**

    H. pyloriEradication to Reduce the Risk of Duodenal Ulcer Recurrence

    Triple Therapy:

    Esomeprazole magnesium delayed-release capsules

    40 mg

    Once Daily for 10 Days

    Amoxicillin

    1000 mg

    Twice Daily for 10 Days

    Clarithromycin

    500 mg

    Twice Daily for 10 Days

    Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

    40mg†

    ‡Twice Daily

    * [See Clinical Studies (14.1).] The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4 to 8 weeks, an additional 4 to 8 weeks of treatment may be considered.

    ** Controlled studies did not extend beyond six months.

    *** If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.

    + Doses over 1 mg/kg/day have not been studied.

    † The dosage of esomeprazole magnesium delayed-release capsules in patients with pathological hypersecretory conditions varies with the individual patient. Dosage regimens should be adjusted to individual patient needs.

    ‡ Doses up to 240 mg daily have been administered [see Drug Interactions (7)].

    Please refer to amoxicillin and clarithromycin prescribing information for Contraindications, Warnings, and dosing in elderly and renally-impaired patients.

    Special Populations

    Hepatic Insufficiency

    In patients with mild to moderate liver impairment (Child Pugh Classes A and B), no dosage adjustment is necessary. For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of esomeprazole magnesium delayed-release capsules should not be exceeded [see Clinical Pharmacology (12.3)].

    Directions for use specific to the route and available methods of administration for each of these dosage forms are presented in Table 2.

    Table 2: Administration Options

    Administration Options

    (See text following table for additional instructions.)

    Dosage Form

    Route

    Options

    Delayed-Release Capsules

    Oral

    Capsule can be swallowed whole.

    -or-

    Capsule can be opened and mixed with applesauce.

    Delayed-Release Capsules

    Nasogastric Tube

    Capsule can be opened and the intact granules emptied into a syringe and delivered through the nasogastric tube.

    Esomeprazole magnesium delayed-release capsules should be swallowed whole.

    Alternatively, for patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the esomeprazole magnesium delayed-release capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately: do not store for future use. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. If the granules/applesauce mixture is not used in its entirety, the remaining mixture should be discarded immediately.

    For patients who have a nasogastric tube in place, esomeprazole magnesium delayed-release capsules can be opened and the intact granules emptied into a 60 mL catheter tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering esomeprazole magnesium through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube into the stomach. After administering the granules, the nasogastric tube should be flushed with additional water. Do not administer the granules if they have dissolved or disintegrated.

    The mixture must be used immediately after preparation.

  • Harmon Face Values Minoxidil | Kroger Company
    No Recall

    Harmon Face Values Minoxidil | Kroger Company

    Harmon Face Values Minoxidil | Kroger Company
    • take only as directed - see Liver warning • use dose cup • do not exceed 4 doses per 24 hrs

    adults & children 12 yrs & over

    30 mL (2 TBSP) every 6 hrs

    children 4 to under 12 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing Directions - Daytime • take only as directed - see Liver warning • use dose cup • do not exceed 4 doses per 24 hrs

    adults & children 12 yrs & over

    30 mL (2 TBSP) every 4 hrs

    children 6 to under 12 yrs

    15 mL (1 TBSP) every 4 hrs

    children 4 to under 6 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing Directions - Daytime • take only as directed - see Liver warning • use dose cup • do not exceed 4 doses per 24 hrs

    adults & children 12 yrs & over

    30 mL (2 TBSP) every 4 hrs

    children 6 to under 12 yrs

    15 mL (1 TBSP) every 4 hrs

    children 4 to under 6 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing